-
The Association Between Radiation-Induced miR-208a, Cancer Recurrence and Death Risk in Patients with Non-Small Cell Lung Cancer
11 Oct 2025 10:37 GMT
… small cell lung cancer (NSCLC) and small cell lung cancer according to … of various tumors including lung cancer by directly regulating … such as EGFR, ALK, KRAS, and others, which have … in non-small cell lung cancer mechanomedicine: deciphering the signaling …
-
Lilly to present new clinical data for Verzenio and multiple novel pipeline programMEs at the 2025 ESMO annual meeting
14 Oct 2025 03:32 GMT
… chemotherapy.
Olomorasib (investigational KRAS G12C inhibitor):
In a … KRAS G12C inhibitor, in patients with KRAS G12C-mutant non-small cell lung cancer … inhibitor of the KRAS G12C protein. KRAS is the most … with non-small cell lung cancer (NSCLC), and 1- …
-
Bayer & Kumquat Biosciences initiate phase I study with KRAS G12D inhibitor in patients with KRAS-mutated tumours
09 Oct 2025 11:38 GMT
… KRAS G12D-mutated tumours, such as pancreatic, colorectal and lung cancer … clinical development of investigational KRAS G12D inhibitor KQB548 ( … Pharmaceuticals Division. “Targeting KRAS has been considered … of non-small cell lung cancers. These mutations are …
-
Sotorasib Tablets Market to Expand at a 12.1% CAGR by 2029, Reaching US $3.03 Billion
14 Oct 2025 01:30 GMT
… of non-small cell lung cancer, increasing consciousness about targeted … in detecting methods for KRAS mutations, research, and … with non-small cell lung cancer. To illustrate, the … Application: Non-Small Cell Lung Cancer, Colorectal Cancer, Other Applications …
-
Small Molecule Targeted Cancer Therapy Industry Analysis Report 2025: Key Trends, Drivers, and Forecast Insights
14 Oct 2025 00:00 GMT
… -treat KRAS G12C-mutated non-small cell lung cancer and … 2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, … market-report
Small Cell Lung Cancer Therapeutics Global Market … report/small-cell-lung-cancer-therapeutics-global-market-report …
-
EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13 Oct 2025 23:01 GMT
… EGFR-mutant non-small cell lung cancer (NSCLC), a high selectivity index … oncology programs for therapy-resistant lung cancer include best-in-class reversible … , c-Met inhibitor, and pan-KRAS molecular glue.
For more information …
-
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
13 Oct 2025 13:40 GMT
… synergistic with adagrasib in KRAS G12C mutant tumor … positive) non-small cell lung cancer (NSCLC). OPDIVO® (nivolumab … metastatic non-small cell lung cancer, in combination with YERVOY … cell lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Roche Data At ESMO 2025 Showcase Advances In Science And Cancer Care Across Multiple Tumour Types
13 Oct 2025 07:02 GMT
… , including breast cancers, lung cancers, gastrointestinal and genitourinary cancers … 30-16:42 CEST Lung cancer Alecensa® (alectinib) Final … ALK+) non-small cell lung cancer (NSCLC) #LBA73 late- … in patients with KRAS G12C-positive pancreatic adenocarcinoma …
-
Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types
13 Oct 2025 05:34 GMT
… including breast cancers, lung cancers, gastrointestinal and genitourinary cancers … in patients with KRAS G12C-positive pancreatic … of lung cancer called “extensive stage small cell lung cancer (SCLC … treatment when your lung cancer:
has not progressed …
-
Redefining Precision Oncology: Astellas’ Vision for Transformative Cancer Care
13 Oct 2025 04:22 GMT
… candidate, ASP3082, is a KRAS G12D degrader being evaluated … in clinical studies. KRAS mutations are known to … options for those with KRAS G12D mutations.
Early data … in other KRAS G12D-positive solid tumors, including lung cancer.
Precision-driven …
About
© 1995-2025